Porcilis Ery + Parvo 50ml (25 dose)

4.1 Target species Pigs (sows and gilts). 4.2 Indications for use, specifying the target species For active immunisation of sows and gilts to prevent clinical signs of Erysipelas disease caused by all relevant Erysipelothrix rhusiopathiae serotypes (serotype 1 and 2) and for protection against embryonal and foetal death caused by porcine parvovirus (PPV) infection. E. rhusiopathiae: Onset of immunity: 3 weeks. Duration of immunity: 6 months. Porcine parvovirus (PPV): Duration of immunity: 12 months. 4.3 Contraindications None. 4.4 Special warnings for each target species Vaccinate healthy animals only. 4.5 Special precautions for use Special precautions for use in animals Sick and weak animals should not be vaccinated. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician. 4.6 Adverse reactions (frequency and seriousness) In laboratory studies and field trials Transient increases in body temperature (0.5 °C) within 24 hours may very commonly occur. Mild transient local swelling (Ø 1 – 10 mm) until 8 days after vaccination may very commonly occur. Transient reluctance to move may commonly occur. In post marketing experience In very rare cases, a hypersensitivity reaction may occur. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 4.7 Use during pregnancy, lactation or lay Can be used during pregnancy and lactation. 4.8 Interaction with other medicinal products and other forms of interaction No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.